2. Прохорович Е.А., Верткин А.Л. Хроническая болезнь почек. М.: Эксмо. 2021; 176 с. [Prokhorovich E.A., Vertkin A.L. Chronic kidney disease. Moscow: The Eksmo Publishing House. 2021; 176 pp. (In Russ.)]. ISBN: 978-5-04-158963-9.

3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3(1): 1–150.

4. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395(10225): 709–33.https://dx.doi.org/10.1016/S0140-6736(20)30045-3.

5. Верткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность в клинической практике. Часть 2. Архивъ внутренней медицины. 2011; 2: 20–24. [Vertkin A.L., Rumyantsev M.A., Skotnikov A.S. Comorbidities in clinical experience. Part 2. Arkhiv vnutrenney meditsiny = Archive of Internal Medicine. 2011; 2: 20–24 (In Russ.)]. EDN: RPELWZ.

6. Tsai W.C., Wu H.Y., Peng Y.S. et al. Risk factors for development and progression of chronic kidney disease: A systematic review and exploratory meta-analysis. Medicine (Baltimore). 2016; 95(11): e3013. https://dx.doi.org/10.1097/MD.0000000000003013.

7. Томилина Н.А., Андрусев А.М., Перегудова Н.Г., Шинкарев М.Б. Заместительная терапия терминальной хронической почечной недостаточности. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. Часть первая. Нефрология и диализ. 2017; 19(S): 1–95. [Tomilina N.A., Andrusev A.M., Peregudova N.G., Shinkarev M.B. Renal replacement therapy for end stage renal disease in Russian Federation, 2010–2015. Russian National Renal Replacement Therapy Registry report of Russian Public Organization of Nephrologists «Russian Dialysis Society», part 1. Nefrologiya i dializ = Nephrology and Dialysis. 2017; 19(S): 1–95 (In Russ.)]. EDN: VVTWCL.

8. Кобалава Ж.Д., Виллевальде С.В., Боровкова Н.Ю. с соавт. от имени исследователей программы ХРОНОГРАФ. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией: результаты эпидемиологического исследования ХРОНОГРАФ. Кардиология. 2017; 57(10): 39–44. [Kobalava Zh.D., Villevalde S.V., Borovkova N.Yu. et al. on behalf of the study participants. Prevalence of markers of chronic kidney disease in patients with arterial hypertension: results of epidemiological trial CHRONOGRAF. Kardiologiya = Cardiology. 2017; 57(10): 39–44 (In Russ.)]. https://dx.doi.org/10.18087/cardio.2017.10.10041. EDN: ZIZYGV.

9. See E.J., Jayasinghe K., Glassford N. et al. Long-term risk of adverse outcomes after acute kidney injury: A systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int. 2019; 95(1): 160–72.https://dx.doi.org/10.1016/j.kint.2018.08.036.

10. Major R.W., Cheng M.R.I., Grant R.A. et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018; 13(3): e0192895. https://dx.doi.org/10.1371/journal.pone.0192895.

11. Yu X., Yuan Z., Lu H. et al. Relationship between birth weight and chronic kidney disease: evidence from systematics review and two-sample Mendelian randomization analysis. Hum Mol Genet. 2020; 29(13): 2261–74. https://dx.doi.org/10.1093/hmg/ddaa074.

12. Major R.W., Cheung C.K., Gray L.J., Brunskill N.J. Statins and Cardiovascular Primary Prevention in CKD: A meta-analysis. Clin J Am Soc Nephrol. 2015; 10(5): 732–39. https://dx.doi.org/10.2215/CJN.07460714.

13. Wang X.R., Zhang J.J., Xu X.X., Wu Y.G. Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2019; 41(1): 244–56.https://dx.doi.org/10.1080/0886022X.2019.1595646.

14. Xie X., Liu Y., Perkovic V. et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A Bayesian Network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016; 67(5): 728–41.https://dx.doi.org/10.1053/j.ajkd.2015.10.011.

15. Alizadeh S., Esmaeili H., Alizadeh M. et al. Metabolic phenotypes of obese, overweight, and normal weight individuals and risk of chronic kidney disease: a systematic review and meta-analysis. Arch Endocrinol Metab. 2019; 63(4): 427–37.https://dx.doi.org/10.20945/2359-3997000000149.

16. Upadhyay A., Earley A., Lamont J.L. et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012; 157(4): 251–62. https://dx.doi.org/10.7326/0003-4819-157-4-201208210-00005.

17. Thomas G., Sehgal A.R., Kashyap S.R. et al. Metabolic syndrome and kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011; 6(10): 2364–73. https://dx.doi.org/10.2215/CJN.02180311.

18. Coresh J., Astor B.C., Greene T. et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41(1): 1–12.https://dx.doi.org/10.1053/ajkd.2003.50007.

19. Eriksson D., Goldsmith D., Teitsson S. et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016; 17(1): 97. https://dx.doi.org/10.1186/s12882-016-0312-9.

20. Astor B.C., Coresh J., Heiss G. et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2006; 151(2): 492–500. https://dx.doi.org/10.1016/j.ahj.2005.03.055.

21. Neild G.H. Life expectancy with chronic kidney disease: An educational review. Pediatr Nephrol. 2017; 32(2): 243–48.https://dx.doi.org/10.1007/s00467-016-3383-8.

22. Mohanram A., Zhang Z., Shahinfar S. et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004; 66(3): 1131–38. https://dx.doi.org/10.1111/j.1523-1755.2004.00863.x.

23. Jing Z., Weijie Y., Nan Z. et al. Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One 2012; 7(8): e43655. https://dx.doi.org/10.1371/journal.pone.0043655.

24. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–200.https://dx.doi.org/10.1093/eurheartj/ehw128

25. Artunc F., Risler T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transplant. 2007; 22(10): 2900–8. https://dx.doi.org/10.1093/ndt/gfm316.

26. Jaakkola P., Mole D.R., Tian Y.M. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292(5516): 468–72. https://dx.doi.org/10.1126/science.1059796.

27. Vogel S., Wottawa M., Farhat K. et al. Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent cofilin phosphorylation. J Biol Chem. 2010; 285(44): 33756–63.https://dx.doi.org/10.1074/jbc.M110.132985.

28. Locatelli F., Fishbane S., Block G.A., Macdougall I.C. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol. 2017; 45(3):187–99. https://dx.doi.org/10.1159/000455166.

29. Besarab A., Provenzano R., Hertel J. et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015; 30(10): 1665–73. https://dx.doi.org/10.1093/ndt/gfv302.

30. Shutov E., Sułowicz W., Esposito C. et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: A phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant. 2021; 36(9): 1629–39.https://dx.doi.org/10.1093/ndt/gfab057.

31. Fishbane S., El-Shahawy M.A., Pecoits-Filho R. et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol. 2021; 32(3): 737–55. https://dx.doi.org/10.1681/ASN.2020081150.

32. Coyne D.W., Roger S.D., Shin S.K. et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int. Rep. 2021; 6(3): 624–35. https://dx.doi.org/10.1016/j.ekir.2020.11.034.

33. Barratt J., Andric B., Tataradze A. et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021; 36(9): 1616–28.https://dx.doi.org/10.1093/ndt/gfab191.

34. European Medicines Agency. Assessment Report .EVRENZO. 24 June 2021. URL: https://www.ema.europa.eu/en/documents/assessment-report/evrenzo-epar-public-assessment-report_en.pdf (date of access – 01.08.2022).

35. Fishbane S., Pollock C.A., El-Shahawy M.A. ROCKIES: An international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract TH-OR022]. J Am Soc Nephrol. 2019; 30: 6.

36. Csiky B., Schomig M., Esposito C. et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a european phase 3, randomized, open-label, active-controlled study (PYRENEES). Adv Ther. 2021; 38(10): 5361–80. https://dx.doi.org/10.1007/s12325-021-01904-6.

37. Charytan C., Manllo-Karim R., Martin E.R. et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021; 6(7): 1829–39. https://dx.doi.org/10.1016/j.ekir.2021.04.007.

38. Provenzano R., Shutov E., Eremeeva L. et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021; 36(9): 1717–30. https://dx.doi.org/10.1093/ndt/gfab051.

39. Шутов Е.В., Горелова Е.Н., Сороколетов С.М. Ингибиторы пролилгидроксилазы индуцируемого гипоксией фактора в лечении анемии больных с хронической болезнью почек. Эффективная фармакотерапия. 2022; 18(3): 22–28. [Shutov E.V., Gorelova E.N., Sorokoletov S.M. Hypoxia-inducible factor prolyl hydroxylase inhibitors in the treatment of anemia in patients with chronic kidney disease. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2022; 18(3): 22–28 (In Russ.)].https://dx.doi.org/10.33978/2307-3586-2022-18-3-22-28. EDN: QSMOWE.

40. Kidney Disease: Improving Global Outcomes (KDIGO). Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 4(2): 279–335.

41. Pfeffer M.A., Burdmann E.A., Chen C.Y. et al.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361(21): 2019–32. https://dx.doi.org/10.1056/NEJMoa0907845.

42. Клинические рекомендации. Анемия при хронической болезни почек. Национальное общество детских гематологов, онкологов, Национальное гематологическое общество. Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 623. Доступ: https://cr.minzdrav.gov.ru/schema/623_4 (дата обращения – 01.08.2022). [Clinical guidelines. Anemia in chronic kidney disease. National Society of Pediatric Hematologists, Oncologists, National Hematological Society. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2020. ID: 623.URL: https://cr.minzdrav.gov.ru/schema/623_4 (date of access – 01.08.2022) (In Russ.)].

43. Lippi G., Franchini M., Favaloro E.J. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost. 2010; 36(5): 537–49. https://dx.doi.org/10.1055/s-0030-1255448.